The company's current portfolio consists of 146 products authorised for distribution at the US marketplace and 54 abbreviated new drug applications (ANDAs) pending approval with the USFDA.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2UQ8Lyg
via IFTTT
0 comments:
Post a Comment